News | January 02, 2025
Innovent inks agreement with Roche for Novel DLL3 ADC
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
SPARC to receive 55% equity in Tiller Therapeutics
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Subscribe To Our Newsletter & Stay Updated
